ES8200857A1 - Procedimiento de preparacion de un nuevo eter basico o de una sal de adicion acida o sal cuaternaria del mismo,farma- ceuticamente aceptable - Google Patents
Procedimiento de preparacion de un nuevo eter basico o de una sal de adicion acida o sal cuaternaria del mismo,farma- ceuticamente aceptableInfo
- Publication number
- ES8200857A1 ES8200857A1 ES497717A ES497717A ES8200857A1 ES 8200857 A1 ES8200857 A1 ES 8200857A1 ES 497717 A ES497717 A ES 497717A ES 497717 A ES497717 A ES 497717A ES 8200857 A1 ES8200857 A1 ES 8200857A1
- Authority
- ES
- Spain
- Prior art keywords
- phenyl
- alkyl
- group
- general formula
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000002170 ethers Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000002082 anti-convulsion Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 abstract 1
- 229960002456 hexobarbital Drugs 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU79EE2715A HU179164B (en) | 1979-12-14 | 1979-12-14 | Process for producing cycloalkyl-ethers of alkanolamines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES497717A0 ES497717A0 (es) | 1981-11-16 |
| ES8200857A1 true ES8200857A1 (es) | 1981-11-16 |
Family
ID=10995882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES497717A Expired ES8200857A1 (es) | 1979-12-14 | 1980-12-12 | Procedimiento de preparacion de un nuevo eter basico o de una sal de adicion acida o sal cuaternaria del mismo,farma- ceuticamente aceptable |
Country Status (27)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212188A (en) * | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| US5242934A (en) * | 1992-03-02 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5242935A (en) * | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5227385A (en) * | 1992-03-13 | 1993-07-13 | Wake Forest University | Method for treatment of neurodegenerative diseases |
| US5288872A (en) * | 1992-03-13 | 1994-02-22 | Wake Forest University | Compounds for treatment of neurodegenerative diseases |
| US5187169A (en) * | 1992-04-10 | 1993-02-16 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5276043A (en) * | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5214060A (en) * | 1992-04-10 | 1993-05-25 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5232932A (en) * | 1992-05-21 | 1993-08-03 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5248690A (en) * | 1992-07-07 | 1993-09-28 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5242916A (en) * | 1992-07-07 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| JPH0626170A (ja) * | 1992-07-09 | 1994-02-01 | Yodogawa Steel Works Ltd | 壁板材の取付構造 |
| JPH06193226A (ja) * | 1992-12-26 | 1994-07-12 | Yodogawa Steel Works Ltd | 壁板材の取付構造 |
| KR100381558B1 (ko) * | 1994-07-01 | 2003-08-19 | 에지스 지오기스제르기아르 알티. | 약제조성물및이의제조방법 |
| HU214588B (hu) * | 1994-07-01 | 1998-04-28 | EGIS Gyógyszergyár Rt. | Eljárás bicikloheptán-származékot tartalmazó, CCK-rendszer gátló hatású gyógyászati készítmények előállítására |
| US5652270A (en) * | 1994-07-01 | 1997-07-29 | Egis Gyogyszergyar Rt | Pharmaceutical compositions containing bicycloheptane ether amines and a process for the preparation thereof |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| HU226061B1 (en) * | 1996-10-17 | 2008-04-28 | Egis Gyogyszergyar Nyilvanosan | 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation |
| HUP9900445A2 (hu) * | 1999-02-24 | 2001-06-28 | EGIS Gyógyszergyár Rt. | Eljárás (1R,2S,4R)-(-)-N,N-(dimetilamino-etoxi)-2-fenil-1,7,7-trimetil-biciklo[2.2.1]heptán előállítására és ennek köztiterméke |
| HU227114B1 (en) | 1999-05-11 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same |
| US6335372B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Treatment of obsessive compulsive disorder |
| FI20002612A0 (fi) * | 2000-11-28 | 2000-11-28 | Orion Yhtymae Oyj | Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi |
| HUP0103017A3 (en) * | 2001-07-18 | 2004-05-28 | Egis Gyogyszergyar Nyilvanosan | Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use |
| GB0306604D0 (en) * | 2003-03-21 | 2003-04-30 | Curidium Ltd | Second medical use |
| WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| HUP0301537A3 (en) * | 2003-06-03 | 2005-07-28 | Egis Gyogyszergyar Nyilvanosan | Deramcyclane fumarate tablets and process for producing them |
| KR101493508B1 (ko) * | 2013-02-18 | 2015-02-16 | 오스템임플란트 주식회사 | 치아 미백 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE581863A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1959-08-06 | |||
| GB895050A (en) * | 1960-01-29 | 1962-04-26 | Boehringer & Soehne Gmbh | New basic ethers |
| DE1108684B (de) * | 1960-01-29 | 1961-06-15 | Boehringer & Soehne Gmbh | Verfahren zur Herstellung neuer basischer AEther |
| AT264495B (de) * | 1963-08-18 | 1968-09-10 | Egyt Gyogyszervegyeszeti Gyar | Verfahren zur Herstellung von neuen basischen Cycloheptanoläthern |
| GB1085969A (en) * | 1965-08-11 | 1967-10-04 | Glidden Co | Insectiphobic compositions comprising terpene derivatives |
| US4118499A (en) * | 1975-10-15 | 1978-10-03 | Glaxo Laboratories Limited | Anti-anxiety and anti-parkinsonian 1-aminoalkyl-2-endo-chloro-7,7-dimethylnorbornanes |
| JPS6034925B2 (ja) * | 1979-07-31 | 1985-08-12 | 帝人株式会社 | 持続性鼻腔用製剤およびその製造法 |
-
1979
- 1979-12-14 HU HU79EE2715A patent/HU179164B/hu unknown
-
1980
- 1980-12-09 GB GB8039376A patent/GB2065122B/en not_active Expired
- 1980-12-10 YU YU3111/80A patent/YU42367B/xx unknown
- 1980-12-10 BE BE1/10069A patent/BE886579A/fr not_active IP Right Cessation
- 1980-12-10 SE SE8008680A patent/SE451132B/sv not_active IP Right Cessation
- 1980-12-10 IL IL61685A patent/IL61685A/xx not_active IP Right Cessation
- 1980-12-11 JP JP17520880A patent/JPS56123953A/ja active Granted
- 1980-12-11 FR FR8026269A patent/FR2471968B1/fr not_active Expired
- 1980-12-11 DD DD80225942A patent/DD155320A5/de not_active IP Right Cessation
- 1980-12-11 NL NL8006722A patent/NL193907C/nl not_active IP Right Cessation
- 1980-12-11 DK DK528980A patent/DK156825C/da not_active IP Right Cessation
- 1980-12-11 AT AT0601380A patent/AT374449B/de not_active IP Right Cessation
- 1980-12-11 CS CS808736A patent/CS216544B2/cs unknown
- 1980-12-11 US US06/215,154 patent/US4342762A/en not_active Expired - Lifetime
- 1980-12-11 AU AU65293/80A patent/AU539173B2/en not_active Expired
- 1980-12-11 PL PL1980228392A patent/PL127036B1/pl unknown
- 1980-12-11 CH CH9133/80A patent/CH649986A5/de not_active IP Right Cessation
- 1980-12-11 FI FI803858A patent/FI76783C/fi not_active IP Right Cessation
- 1980-12-12 IT IT8026587A patent/IT1209377B/it active
- 1980-12-12 NO NO803764A patent/NO150638C/no not_active IP Right Cessation
- 1980-12-12 IE IE2612/80A patent/IE51733B1/en not_active IP Right Cessation
- 1980-12-12 ES ES497717A patent/ES8200857A1/es not_active Expired
- 1980-12-12 CA CA000366719A patent/CA1155115A/en not_active Expired
- 1980-12-12 UA UA3219704A patent/UA5566A1/uk unknown
- 1980-12-12 SU SU3219704A patent/SU1253425A3/ru active
- 1980-12-12 GR GR63641A patent/GR72509B/el unknown
- 1980-12-15 DE DE3047142A patent/DE3047142C2/de not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES8200857A1 (es) | Procedimiento de preparacion de un nuevo eter basico o de una sal de adicion acida o sal cuaternaria del mismo,farma- ceuticamente aceptable | |
| MX9203165A (es) | Derivados de succinimida y composicion farmaceutica que los contiene . | |
| DE69003200D1 (de) | Arylsubstituierte Aminderivate verwendbar in der Krebstherapie. | |
| DK0527494T3 (da) | Præparat indeholdende rhodacyanin-farvestoffer til behandling af cancer | |
| MX9202438A (es) | Esteroides 3-carboxi insaturados substituidos en la posicion 17 beta, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| ES486824A1 (es) | Procedimiento para la preparacion de nuevos derivados de 4- (naftilmetil) piperidinas | |
| ES444870A1 (es) | Procedimiento para preparar derivados de oxadiazolinona. | |
| FI833453A0 (fi) | Terapeutiska medel | |
| ES8105704A1 (es) | Procedimiento de preparacion de nuevos eteres oximas, de sussales de adicion acidas y de sus derivados amonicos cuater- narios | |
| ES8101589A1 (es) | Un procedimiento para la preparacion de nuevos compuestos iminicos heterociclicos. | |
| SE8303913L (sv) | Heterocykliska foreningar | |
| DK0485219T3 (da) | Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser | |
| DK0832079T3 (da) | Antiiskæmiske hydroxylaminderivater og farmaceutiske sammensætninger | |
| ES8404980A1 (es) | Un procedimiento para preparar guanidino-fenilamidinas heterociclicas sustituidas. | |
| ES8307258A1 (es) | "procedimiento para la preparacion de nuevas cefalosporinas". | |
| ES8403130A1 (es) | Procedimiento para la preparacion de tienobenzodiazepinonas sustituidas. | |
| IL61233A (en) | Guanidino thiazolylalkylamino(alkylthioalkylamino)nitro pyrroles,process for their preparation and pharmaceutical compositions containing them | |
| DK601883D0 (da) | Phenyl-propanolderivater | |
| ES476232A1 (es) | Procedimiento para la obtencion de derivados del fosfonilu- reidobenceno. | |
| IL70103A (en) | 4-(6,7-dimethoxyquinazolin-4-yl)-semicarbazides,their preparation and pharmaceutical compositions containing them |